End of Year Note
By Katherine Yang-Iott
2022 seemed to have gone by especially fast with the relaxing of covid restrictions, more in-person interactions, and even a flight or two for some. For the G&A Team, we’ve had our most research-intense year yet.
We kicked off our year by opening up the 2022 World Class RIM Study, where we had more companies participate in our benchmark industry standard than ever before (n=76). You can catch up on what we’ve been working on, thinking about, and discussing with our clients and research community through our Spring/Summer and Fall/Winter blog series. A few popular posts I’d recommend are here (business benefits from RIM investments) and here (evolving the regulatory workforce). You might have also read some of our publications focusing on ‘what’s next’ in Pharmaceutical Commerce and Journal of mHealth.
Preeya and Steve have been continually developing and updating our Data Governance and Data Quality Sustainability model, along with detailed remits for the evolving regulatory operations organizations. Kelly has kept us all updated on IDMP/SPOR developments throughout the year and our Strategic KPI and Continuous Improvement Toolkit is worth digging in to given how many companies are currently working on maturing their metrics and CI programs. We also just added our 2022 Regulatory Service Provider Report with TAM. We are constantly adding new content and sharing what we learned in our Executive Lounge (EL), so if your organization is not already part of our EL membership, here’s how to join.
As for research reports, you’ll find some very interesting information in our 3 pulse surveys this year: 2022 Covid-19 Regulatory Impact follow-up study (n=173), the Registration Data Management Pulse Survey (n=27) and the latest Regulatory Intelligence Study (n=55). If your company participated in the study, you have access to the reports. To learn more about how to be an active member of our research community, please send us a note.